Stereotaxis, Inc. (STXS) stock
STXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/3018% below fair value
$0.88+0.08 (+9.89%)
Close on Nov 17, 2026Market cap $88.39MP/E –Yield –
Stereotaxis r&d expenses
Research and development expenses are spending on new products and technology.
Stereotaxis's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.04M, up 7.2% year over year. For fiscal 2025 it was $9.38M, down 3.9% from the year before. Over ten years it grew 4.1% a year on average. The highest annual figure on record is $14.26M in fiscal 2009.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.38M | -3.9% |
| FY2024 | Dec 31, 2024 | $9.76M | -5.0% |
| FY2023 | Dec 31, 2023 | $10.27M | -2.7% |
| FY2022 | Dec 31, 2022 | $10.56M | +3.5% |
| FY2021 | Dec 31, 2021 | $10.20M | +25.3% |
| FY2020 | Dec 31, 2020 | $8.14M | -9.8% |
| FY2019 | Dec 31, 2019 | $9.02M | +9.8% |
| FY2018 | Dec 31, 2018 | $8.22M | +22.6% |
| FY2017 | Dec 31, 2017 | $6.70M | +22.2% |
| FY2016 | Dec 31, 2016 | $5.49M | -12.2% |
| FY2015 | Dec 31, 2015 | $6.25M | +21.2% |
| FY2014 | Dec 31, 2014 | $5.16M | -9.1% |
| FY2013 | Dec 31, 2013 | $5.67M | -32.5% |
| FY2012 | Dec 31, 2012 | $8.41M | -34.8% |
| FY2011 | Dec 31, 2011 | $12.89M | +5.2% |
| FY2010 | Dec 31, 2010 | $12.24M | -14.1% |
| FY2009 | Dec 31, 2009 | $14.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.39M | +34.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.40M | +2.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.71M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.55M | +3.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.78M | -21.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.35M | +4.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.79M | +26.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.45M | -8.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.27M | -14.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.24M | -18.3% |
| Q4 FY2023 | Dec 31, 2023 | $2.21M | -7.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.67M | -5.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.65M | -8.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.75M | +12.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.40M | -8.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.82M | +12.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.89M | +6.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.45M | +3.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.62M | +24.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.50M | +28.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.72M | +37.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.37M | +12.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.10M | +29.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.95M | +11.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.98M | -26.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.11M | -28.7% |
| Q4 FY2019 | Dec 31, 2019 | $1.62M | -27.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.75M | -12.5% |
| Q2 FY2019 | Jun 30, 2019 | $2.70M | +32.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.96M | +50.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.22M | +28.7% |
| Q3 FY2018 | Sep 30, 2018 | $2.00M | +23.5% |
| Q2 FY2018 | Jun 30, 2018 | $2.03M | +15.7% |
| Q1 FY2018 | Mar 31, 2018 | $1.96M | +22.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.73M | +33.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.62M | +25.1% |
| Q2 FY2017 | Jun 30, 2017 | $1.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.30M | – |
See a number that looks wrong?